Plasmid

Porton Advanced and Bennu Biotherapeutics Announced a Strategic Partnership to Accelerate Cell Therapy Development for Solid Tumors

Retrieved on: 
Monday, March 13, 2023
Proton, Neoplasm, Plasmid, Cell, Gene, CDMO, TIL, Messenger, Partnership, Pharmaceutical industry, Vaccine

SUZHOU, China, March 13, 2023 /PRNewswire/ -- On March 7th, 2023, Suzhou Porton Advanced Solutions Ltd. (Porton Advanced) and Bennu Biotherapeutics (Bennubio) announced a strategic partnership to advance cell and gene therapy R&D pipelines.

Key Points: 
  • SUZHOU, China, March 13, 2023 /PRNewswire/ -- On March 7th, 2023, Suzhou Porton Advanced Solutions Ltd. (Porton Advanced) and Bennu Biotherapeutics (Bennubio) announced a strategic partnership to advance cell and gene therapy R&D pipelines.
  • As an end-to-end gene and cell therapy service CDMO, Porton Advanced provides comprehensive solutions covering plasmids, cell therapy, gene therapy, oncolytic virus, mRNA therapy, and bacterial therapy.
  • Under this strategic agreement, Porton Advanced will provide CDMO services for multiple pipelines for gene and cell therapy, including plasmids, virus, TIL, TCR-T, and Treg, to Bennu Biotherapeutics.
  • Ms. Zhao Ping, Co-founder and CEO of Bennu Biotherapeutics, said, "We can advance our process development and production by utilizing the advanced process development technologies provided by Porton Advanced.

Charles River Launches Helper Plasmid to Streamline Adeno-Associated Viral Vector Manufacturing

Retrieved on: 
Thursday, March 9, 2023
Health, Medical Devices, General Health, Research, Science, Pharmaceutical, Biotechnology, Role, ATMP, Associate Director of National Intelligence and Chief Information Officer, Education minister, CDMO, HQ, GEN, DNA, RG, Patient, AAV, History, GMP, Congress, Doctor of Philosophy, European Spatial Development Perspective, Plasmid, Tecmar, Vaccine, Pharmaceutical industry

Alongside a wealth of expert speakers and panel discussions, Ramin Baghirzade, PhD, Senior Director, Global Head Commercial, Gene Therapy CDMO Services will present: The Role of Plasmid DNA in Expediting Gene Therapy Manufacturing and Beyond.

Key Points: 
  • Alongside a wealth of expert speakers and panel discussions, Ramin Baghirzade, PhD, Senior Director, Global Head Commercial, Gene Therapy CDMO Services will present: The Role of Plasmid DNA in Expediting Gene Therapy Manufacturing and Beyond.
  • The addition of pHelper plasmids follows the launch of the eXpDNA™ plasmid manufacturing platform , established over decades of plasmid DNA CDMO scale-up experience, which significantly reduces plasmid production turnaround time for advanced therapy medical product (ATMP) and vaccine developers.
  • In recent years, Charles River has significantly broadened its cell and gene therapy portfolio with several acquisitions and recent expansions to simplify complex supply chains and meet growing global demand for plasmid DNA, viral vector, and cell therapy services.
  • Combined with the Company’s legacy testing services, Charles River offers an industry-leading “concept-to-cure” solution for advanced therapies.

Aldevron and Evanoa Sign Licensing Agreement

Retrieved on: 
Wednesday, March 8, 2023
Other Manufacturing, Research, Genetics, Health Technology, Manufacturing, Biotechnology, General Health, Health, Science, Other Science, Protein, CSO, Escherichia coli, Immortalised cell line, Vaccine, DNA, Partnership, Patient, AAV, RNA, Fermentation, Plasmid, Antibiotics

Evanoa Bioscience Inc., a cell line developer for biologics manufacturing, together with Aldevron®, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, today announced the signing of a licensing agreement for two E. coli strains to be used in plasmid production.

Key Points: 
  • Evanoa Bioscience Inc., a cell line developer for biologics manufacturing, together with Aldevron®, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, today announced the signing of a licensing agreement for two E. coli strains to be used in plasmid production.
  • Strains developed by Evanoa have been shown to produce as much as two times more plasmid per cell and total plasmid titer per fermentation.
  • Based on these current favorable data, Aldevron has licensed the strains to further explore their utility in different environments.
  • While these results demonstrate significant production improvement for several plasmids via the Aldevron® AAV platform, Evanoa technology can be applied for the improvement of any type of plasmid.

Catalent Expands UpTempo ℠ AAV Platform to Accelerate Development of Gene Therapies

Retrieved on: 
Thursday, March 9, 2023
CGMP, HEK293, EMA, Glossary, Patient, AAV, European Center for Constitutional and Human Rights, Transfection, Plasmid, Cell, Vaccine, Catalent

SOMERSET, N.J., March 9, 2023 /PRNewswire-PRWeb/ -- Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the expansion of its UpTempo ℠  platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors. The platform now includes an in-house, clonal HEK293 cell line, and off-the-shelf plasmids to support a robust supply chain for the development and manufacture of gene therapies, and the reduction of timelines to first-in-human clinical evaluation.

Key Points: 
  • Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the expansion of its UpTempo ℠ platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors.
  • The platform now includes an in-house, clonal HEK293 cell line, and off-the-shelf plasmids to support a robust supply chain for the development and manufacture of gene therapies, and the reduction of timelines to first-in-human clinical evaluation.
  • SOMERSET, N.J., March 9, 2023 /PRNewswire-PRWeb/ -- Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the expansion of its UpTempo ℠ platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors.
  • "Speed to patients is paramount for gene therapy innovators, and as such, we've seen multiple customers requesting and signing up for the UpTempo platform.

Porton Advanced Collaborates with DanausGT to Accelerate the Development of Gene and Cell Therapy

Retrieved on: 
Thursday, March 2, 2023
Messenger, Research, Gene editing, CDMO, Patient, CSO, Therapy, CGT, Plasmid, Anemia, Partnership, Pharmaceutical industry, IND

SUZHOU,China, March 2, 2023 /PRNewswire/ -- Porton Advanced Solutions Ltd. (Porton Advanced) and DanausGT Biotechnology Co., Ltd. (DanausGT) announced on February 27, 2023, a strategic collaboration in gene and cell therapy pipelines to expedite the development of innovative therapeutics.

Key Points: 
  • SUZHOU,China, March 2, 2023 /PRNewswire/ -- Porton Advanced Solutions Ltd. (Porton Advanced) and DanausGT Biotechnology Co., Ltd. (DanausGT) announced on February 27, 2023, a strategic collaboration in gene and cell therapy pipelines to expedite the development of innovative therapeutics.
  • As an end-to-end gene and cell therapy service provider, Porton Advanced CDMO offers comprehensive solutions covering plasmids, cell therapy, gene therapy, oncolytic virus, mRNA therapy, and bacterial therapy.
  • DanausGT has established multiple R&D pipelines, and Porton Advanced will offer gene and cell therapy CDMO solutions to DanausGT, including plasmid, virus, and cell therapy products.
  • "We make gene editing technology and cell therapy to treat various diseases and work on therapy development for patient-centered care and clinical value.

Porton Advanced and Yinjia Biosciences Partner to Enhance CDMO Technology Platform

Retrieved on: 
Friday, February 24, 2023
Messenger, Plasmid, Partnership, Quality control, CGT, Therapy, Patient, Vaccine

Porton Advanced CDMO offers end-to-end gene and cell therapy services covering plasmids, cell therapy, gene therapy, oncolytic virus, mRNA therapy, and bacterial therapy.

Key Points: 
  • Porton Advanced CDMO offers end-to-end gene and cell therapy services covering plasmids, cell therapy, gene therapy, oncolytic virus, mRNA therapy, and bacterial therapy.
  • Yinjia Biosciences focuses on high-quality core protein raw materials and also offers companion diagnostics products for innovative adjuvant therapies.
  • Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
  • Porton Advanced will continue to advance its technology and capabilities to accelerate the development of CGT to meet clinical needs and empower global partners.

GenScript ProBio and RVAC Medicines Announce Strategic Partnership for GMP Plasmid DNA Manufacturing for mRNA COVID-19 Vaccine Candidate

Retrieved on: 
Wednesday, February 22, 2023
DNA, Biotechnology, Vaccine, Messenger, Infection, Therapy, Plasmid, RSV, RNA, CDI, Partnership, GenScript Biotech, COVID-19, Respiratory syncytial virus, GMP, CDMO

GenScript ProBio will provide GMP plasmid manufacturing service for RVAC Medicines' program, RVM-V001.

Key Points: 
  • GenScript ProBio will provide GMP plasmid manufacturing service for RVAC Medicines' program, RVM-V001.
  • Dr. Brian Min, CEO of GenScript ProBio said, "We are delighted to enter into this strategic partnership with RVAC Medicines.
  • As RVAC advances the development of its mRNA candidates, GenScript ProBio continues to provide high-quality GMP materials critical to the mission, including plasmid DNA and the development of ancillary materials to support mRNA manufacturing process.
  • RVAC Medicines will continue to collaborate with GenScript ProBio to support its mRNA initiatives for both clinical-stage development and commercial stage.

AGC Biologics Supports Commercial Production of Provention Bio’s New Type 1 Diabetes (T1D) Therapy, TZIELD™

Retrieved on: 
Tuesday, January 24, 2023
Biotechnology, Diabetes, Pharmaceutical, Health, CDMO, Food and Drug Administration, Life, Cell therapy, Messenger, Ageing, Perfusion, Patient, AGC, PPQ, Medicine, T1D, Plasmid, Messenger RNA, FDA, Autoimmune disease, CGMP, Viral vector, Fine chemical, Pharmaceutical industry

AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new commercial manufacturing project at its Seattle protein biologics manufacturing site.

Key Points: 
  • AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new commercial manufacturing project at its Seattle protein biologics manufacturing site.
  • The AGC Biologics Seattle campus has produced biologics products for 30 years and has a long history of successful inspections by the FDA and commercial production.
  • “Congratulations to Provention Bio on this game-changing achievement for T1D patients,” said Kevin Ingham, General Manager of AGC Biologics’ Seattle site.
  • “We at AGC Biologics are proud to have helped develop this innovative new medicine and to be manufacturing it for commercial distribution.

Center for Breakthrough Medicines Launches Precision Plasmids™ Manufacturing to Accelerate Advanced Therapies into the Clinic

Retrieved on: 
Thursday, February 2, 2023
Messenger, DNA sequencing, SVP, NGS, Maintenance, Precision, Quality management system, Plasmid, QMS, CAPA, CBM, NO, Tat, GMP, Education, Communities and Justice Directorates, CDMO, Vaccine

KING OF PRUSSIA, Pa., Feb. 2, 2023 /PRNewswire/ -- The Center for Breakthrough Medicines (CBM), a contract development, and manufacturing organization (CDMO), has launched its plasmid manufacturing offering, Precision Plasmids™ to provide phase-appropriate plasmid on-demand for any company seeking to accelerate their path to clinic for cell and gene therapies. CBM offers NO WAIT TIMES for Precision Plasmids™ R&D grade for pre- and early clinical phases, and Precision Plasmids™ Pro grade for toxicology studies, Ph1-2 vector production, or as a starting material for mRNA. Both Precision Plasmids™ R&D and Pro are available now, while Precision Plasmids™ GMP grade will be available in April 2023.

Key Points: 
  • KING OF PRUSSIA, Pa., Feb. 2, 2023 /PRNewswire/ -- The Center for Breakthrough Medicines (CBM), a contract development, and manufacturing organization (CDMO), has launched its plasmid manufacturing offering, Precision Plasmids™ to provide phase-appropriate plasmid on-demand for any company seeking to accelerate their path to clinic for cell and gene therapies.
  • Both Precision Plasmids™ R&D and Pro are available now, while Precision Plasmids™ GMP grade will be available in April 2023.
  • CBM Precision Plasmids™ are of the highest quality, confirmed by Next Generation Sequencing (NGS) to guarantee the reproducibility of vector-based therapies that are manufactured using plasmids.
  • Whether standalone starting material or within CBM's integrated Genesis Vector Manufacturing Solution™ , cell and gene therapy companies can start development and manufacturing today.

Charles River Establishes eXpDNA™ Plasmid Manufacturing Platform to Expedite DNA Programs

Retrieved on: 
Thursday, January 12, 2023
Health, Medical Devices, Other Science, General Health, Research, Science, Pharmaceutical, Shift, Lunch, Tecmar, Plasmid, Secrecy, CRL, DNA, Gene therapy, NYSE, Vaccine, Associate Director of National Intelligence and Chief Information Officer, Miami Beach Convention Center, Good manufacturing practice, Lunches for Learning, Patient, Booth, HQ, CDMO, Good, Doctor of Philosophy, GMP, Cognate, Medical device

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its eXpDNA™ plasmid platform, established from the Company’s contract development and manufacturing (CDMO) and biologics testing experience.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its eXpDNA™ plasmid platform, established from the Company’s contract development and manufacturing (CDMO) and biologics testing experience.
  • The platform leverages Charles River’s expertise in developing, manufacturing, and releasing more than 200 High Quality (HQ) and Good Manufacturing Practice- (GMP) compliant plasmid DNA batches.
  • eXpDNA supports a client’s plasmid DNA strategy by offering a proven, and standardized plasmid platform approach, suitable for plasmid DNA programs across various applications.
  • The eXpDNA plasmid manufacturing platform builds on Charles River’s established plasmid DNA CDMO capabilities and processes, fine-tuned over decades successfully supporting vaccine and advanced therapy clients through clinical trials and beyond.